Activation of latent TGF-beta as a novel anti-inflammatory treatment for traumatic brain injury (TBI)

This Cooperative Agreement award from the Uniformed Services University of the Health Sciences (CFDA 12.750 - Uniformed Services University Medical Research Projects) provides $1,857,850.00 in funding to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. to support research on a novel anti-inflammatory treatment for traumatic brain injury (TBI).

The key objectives of the research project include: 1) Determining the effects of the treatment PSG1 on central nervous system signaling, pathology, and behavior following TBI in mice; 2) Evaluating the impact of PSG1 on systemic immune cell responses and the generation of tissue repair macrophages after TBI; and 3) Assessing how PSG1 influences neuroinflammation and cell-to-cell interactions in the central nervous system following TBI. The University of Minnesota is serving as a sub-awardee, supporting the research on the immune system and microglial/glial cell responses. The award period is from September 16, 2024 to September 15, 2027.